Integrated Biopharma, Inc. has announced its financial results for the quarter ending September 30, 2026. This update is significant as it provides insights into the company's operational performance and financial health.

Integrated Biopharma, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, is a company focused on developing and manufacturing pharmaceutical products. The company trades under the ticker INBP on the OTC exchange and is categorized as a non-accelerated filer and smaller reporting company.

The recent filing, dated November 13, 2026, indicates that Integrated Biopharma issued a press release detailing its financial results for the quarter. The specific outcomes of these results were not disclosed in the filing itself, but the press release is referenced as Exhibit 99.1.

This update may affect various stakeholders, including investors, analysts, and competitors within the pharmaceutical preparations industry. As Integrated Biopharma continues to navigate its financial landscape, the results will likely be scrutinized for indications of growth or challenges.

Looking ahead, details on future actions or filings were not provided in this update. The company will likely continue to communicate its performance and strategic direction in forthcoming reports.

Company Overview and Recent Developments

Integrated Biopharma, Inc. operates from its headquarters located at 225 Long Avenue, Building 15, Hillside, New Jersey, and is incorporated in the state of Delaware. The company has a Central Index Key (CIK) of 0001016504 and is recognized under the SEC file number 001-31668.

As of the filing date, Integrated Biopharma is classified as a smaller reporting company and is not considered an emerging growth company according to the definitions set forth in the Securities Act of 1933 and the Securities Exchange Act of 1934.

The company has undergone several name changes in its history, previously known as Integrated Health Technologies Inc. and Chem International Inc., with the latest name change occurring on September 12, 2002.

While the financial results for the quarter ending September 30, 2026, have been announced, specific figures regarding revenue, net income, or expenses are not disclosed in the filing. Investors and analysts will need to refer to the press release provided as Exhibit 99.1 for detailed financial metrics.

Additionally, the filing does not include any forward-looking statements or guidance regarding future performance, which may be of interest to stakeholders monitoring the company's strategic initiatives and market positioning.